Previous Close | 9.14 |
Open | 9.13 |
Bid | 9.11 x 100 |
Ask | 9.14 x 200 |
Day's Range | 9.06 - 9.27 |
52 Week Range | 8.21 - 11.98 |
Volume | |
Avg. Volume | 369,988 |
Market Cap | 442.867M |
Beta (5Y Monthly) | 0.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.00 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.40 |
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.